Ranbaxy To Announce New Drug Development Tie-Up In May
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's top generic drug firm Ranbaxy Laboratories expects to announce a new tie up with a large multinational drug firm in May to develop new chemical entities at its recently spun-off Life Science Research unit similar to a current deal with GlaxoSmithKline inked in 2003 and expanded last year, the company's chief executive said
You may also be interested in...
Daiichi Sankyo's Majority Stake In Ranbaxy Will Increase Production Capacity In India, Expand Global Footprint In Developing Markets – Japanese Analysts
TOKYO - Daiichi Sankyo will make a foray into the generics business with its Ranbaxy acquisition, and will shift much of its domestic production to Ranbaxy to save costs, analysts in Japan said. However, the Japanese company will not sell its brand drugs through Ranbaxy's distribution channels, nor will the two companies start a joint generics business in Japan, they speculated
Daiichi Sankyo's Majority Stake In Ranbaxy Will Increase Production Capacity In India, Expand Global Footprint In Developing Markets – Japanese Analysts
TOKYO - Daiichi Sankyo will make a foray into the generics business with its Ranbaxy acquisition, and will shift much of its domestic production to Ranbaxy to save costs, analysts in Japan said. However, the Japanese company will not sell its brand drugs through Ranbaxy's distribution channels, nor will the two companies start a joint generics business in Japan, they speculated
Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
NEW DELHI - Japan's Daiichi Sankyo will buy a majority stake in India's top drug maker in a deal that will vault the combined operations into the top 15 pharmaceutical firms globally and end the founding Singh family's role as largest shareholder of Ranbaxy Laboratories